Professor Borislava Mihaylova

Borislava Mihaylova is a Professor of Health Economics at the Wolfson Institute of Population Health, Queen Mary University of London, UK and at the Nuffield Department of Population Health, University of Oxford, UK. Her research on economic aspects of chronic disease treatment and prevention alongside clinical trials (e.g. HPS, SHARP, EMPA-KIDNEY) and meta-analysis (Cholesterol Treatment Trialists’ Collaboration) inform policy by providing evidence for net effects and cost-effectiveness of treatments. Key contributions include evidence that statins are beneficial and cost-effective across categories of patients by age, sex, CVD risk and LDL cholesterol (LDL-C) level with high-intensity statin optimal for most categories except younger women with lower LDL-C and lower CVD risk for whom standard statin regimens are optimal. She served on the European Society of Cardiology Clinical Practice Guidelines Committee (2022-2026).